Shire rival gets approval for generic ADHD drug
The FTSE 100 pharma company, Shire, says the US Food and Drug Administration has approved a rival's application to make a generic version of an attention deficit and hyperactivity disorder (ADHD) drug.
The FTSE 100 pharma company, Shire, says the US Food and Drug Administration has approved a rival's application to make a generic version of an attention deficit and hyperactivity disorder (ADHD) drug.
Actavis has been given the all clear to manufacture a generic form of Adderall XR.
Shire already makes the drug so the suspicion will be that revenues may be hit but the firm says it "continues to expect to deliver good full-year 2012 earnings growth".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Today's update adds though that Shire recognises "there will be multiple dynamics affecting the overall market following the approval of the Actavis generic".
In other words, the FDA's decision could prove problematic.
BS
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Water bills set to rise by 21% a year – how to cut costs
Households could see their water bills soar by roughly 21% annually, but suppliers warn it’s not enough to address essential repairs.
By Oojal Dhanjal Published
-
Should you invest in Canada?
Canada presents a compelling opportunity for investors who want to look beyond the US. Greg Eckel of Canadian General Investments highlights four favourites
By Greg Eckel Published